Triple-negative breast cancer (TNBC) is a distinct breast cancer subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2/neu), and the patients with TNBC are often diagnosed with higher rates of recurrence and metastasis. Because of the absence of ER, PR and HER2/neu expressions, TNBC patients are insensitive to HER2-directed and endocrine therapies available for breast cancer treatment. Here, we report that expression of atypical protein kinase C isoform, PKCk/i, significantly increased and activated in all invasive breast cancer (invasive ductal carcinoma or IDC) subtypes including the TNBC subtype. Because of the lack of targeted therapies for TNBC, we choose to study PKCk/i signaling as a potential therapeutic target for TNBC. Our observations indicated that PKCk/i signaling is highly active during breast cancer invasive progression, and metastatic breast cancers, the advanced stages of breast cancer disease that developed more frequently in TNBC patients, are also characterized with high levels of PKCk/i expression and activation. Functional analysis in experimental mouse models revealed that depletion of PKCk/i significantly reduces TNBC growth as well as lung metastatic colonization. Furthermore, we have identified a PKCk/i-regulated gene signature consisting of 110 genes, which are significantly associated with indolent to invasive progression of human breast cancer and poor prognosis. Mechanistically, cytokines such as TGFb and IL1b could activate PKCk/i signaling in TNBC cells and depletion of PKCk/i impairs NF-jB p65 (RelA) nuclear localization. We observed that cytokine-PKCk/i-RelA signaling axis, at least in part, involved in modulating gene expression to regulate invasion of TNBC cells. Overall, our results indicate that induction and activation of PKCk/i promote TNBC growth, invasion and metastasis. Thus, targeting PKCk/i signaling could be a therapeutic option for breast cancer, including the TNBC subtype.
Breast cancer is a clinically heterogeneous disease and both intra and inter-tumor heterogeneities provide great challenges for developing successful therapies. Expressions (or absence thereof) of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2)/neu are widely used to clinically classify breast tumors into multiple therapeutic groups. 1 The ER/PR-positive and the HER2-positive breast cancer patients could be benefited from endocrine and HER2-targeted therapies. 1 However, triplenegative breast cancers (TNBCs), which represent B12-17% of all breast cancer, 2 lack ER, PR and HER2/neu expressions 2 and are not responsive to therapies targeting these receptors. Therefore, the only systemic therapy available for TNBC is chemotherapy. 3 Furthermore, TNBC is associated with aggressive pathologic features like higher histology grade and mitotic index 4 and often found to be associated with higher rate of metastasis and recurrence leading to limited clinical outcome. [5] [6] [7] [8] Recurrence of TNBC tends to recur within a few years after successful initial treatment 6, 9 and often develops metastasis to the bone, brain and lungs with poor prognosis. 2, 6 Thus, identification of signaling pathways that regulate malignant progression of breast cancer subtypes, especially TNBCs, would be therapeutically important.
In recent years, PKC signaling has been implicated in modulating invasion and metastasis of multiple tumors. 10, 11 The PKC family consists of multiple serine/threonine kinases and the relative contribution of individual PKC isoforms during cancer progression varies due to pleiotropism. 12 PKC isoforms regulate diverse cellular functions such as cell-cycle regulation, cellular survival, cell-cell communications and apoptosis. 13 In particular, atypical PKC isoforms, PKCz and atypical protein kinase C lamda/iota (PKCl/i), are known to be important for chemotaxis, cell polarity, migration and wound healing processes. 14, 15 Aberrations in all these processes are manifested in tumor progression and metastasis.
14 Consistent with these notions, recent studies indicated that atypical PKCs are associated with various human cancers. 10, 11 Importantly, the PKCl/i gene is located at the 3q26.2 genomic region, which is most frequently amplified in human cancer 16, 17 , and overexpression of PKCl/i has been implicated in cancer development in multiple tissues including the lung, 18, 19 pancreas, 20 stomach, 21 colon, 22 esophagus, 23 liver, 24 bile duct, 25 ovary, 17 prostate 26 and brain. 27 Recently, few studies have been reported higher expression of PKCl/i in ER/PRand HER-positive breast cancer and also in lymph node metastases. 28 , 29 Kojima et. al. 28 showed that PKCl/i expression is highly induced in the ER/PR-and HER2-positive IDCs compared with ductal carcinoma in situ (DCIS) and normal breast. PKCl/i forms apical-junctional complexes (AJCs) with other polarity proteins such as partitioning defective 3 homolog (PAR3) and partitioning defective 6 homolog (PAR6), [30] [31] [32] [33] and invasiveness of breast tumor cells was shown to be associated with loss of PKCl/i localization from their apical domains. 28 In addition, predominant nuclear localization of PKCl/i in both normal and atypical ductal hyperplasia (ADH) lesions prompted the concept that PKCl/i might be in an inactive state in these lesions. 28 However, expression and activation of PKCl/i in TNBCs and the functional importance of PKCl/i signaling in relation to invasive breast cancer progression and metastasis are very poorly understood. 10, 11 Here, we studied PKCl/i signaling during invasive progression of TNBC. We utilized expression evaluations in triplenegative IDCs as well as metastatic breast cancers of human patients, in vitro and in vivo functional assays, and global gene expression analysis of human patient samples. We concluded that PKCl/i signaling is an important regulator for invasion and metastatic progression of human breast cancers including triple-negative subtypes.
Results
PKCk/i is highly active in human TNBCs and metastatic breast cancers. To investigate PKCl/i signaling in breast cancer disease progression, we tested expression of PKCl/i in human breast sample cohort, consisting of normal breasts, DCIS and IDC samples of ER-positive, HER2-positive and TNBC subtypes (Figures 1a-d, Supplementary Figure S1a and S1b). Immunohistochemical analysis of PKCl/i expression indicated significant increase in ER-and HER2-positive IDC samples compared with normal breast and DCIS ( Figure 1a, Supplementary Figures S1c and d) and supported previous reports. 28, 29 Importantly, we also observed significant higher expression of PKCl/i in TNBC subtypes compared with normal breast and DCIS (Figures 1a-c, Supplementary  Figures S1c and d) . In all IDC samples, the induced PKCl/i localization was detected in both cytoplasm and nuclei, (Figure 1d and Supplementary Figure S1b ) with a few cases showing focal (5-25%) nuclear staining.
To test the distribution of activated form of PKCl/i, we used a previously validated antibody [34] [35] [36] that selectively recognizes PKCl/i molecules, phosphorylated at threonine 555 (T555) and threonine 563 (T563) residues in the catalytic domain 15, 37 (phospho-PKCl/i). We observed that phosphoPKCl/i levels were also significantly increased from normal breast to DCIS to IDC samples of all clinical subtypes (Figures 1b-d, Supplementary Figures S1e and f) . Interestingly, in contrast to total PKCl/i, we observed predominant nuclear localization of phospho-PKCl/i in all IDC samples (Figure 1d and Supplementary Figure S1b) . As phosphorylation event (specifically at T555) is believed to prime activation of PKCl/i, 38 our observations indicate predominant localization of active PKCl/i in the nuclei of breast tumor cells and oppose the idea that inactive PKCl/i localizes within nuclei, as suggested earlier. 28 Next, we collected multiple human metastatic breast cancer samples (n ¼ 10) from distal organs such as the bone, brain, chest wall, colon, gallbladder, liver, lung and ovary to test PKCl/i expression and phosphorylation ( Figure 1e ). We found that similar to IDC and lymph node metastasis, 29 PKCl/i is highly expressed and phosphorylated in the metastatic breast cancers with predominant nuclear localization of phosphoPKCl/i (Figure 1e ). Collectively, these results and previous reports 28, 29 strongly correlate higher expression and activation of PKCl/i with invasive progression of breast cancer including TNBC subtypes to develop local and distal metastasis.
PKCk/i regulates epithelial morphology, invasion and migration of triple-negative breast cancer cells. On the basis of our observation in human patient samples, we hypothesized that PKCl/i signaling could promote invasion and metastasis of TNBC. Therefore, we specifically depleted PKCl/i in MDA-MB-231 cells, a highly invasive and metastatic TNBC cell line, via RNA interference (RNAi) (Figure 2a and Supplementary Figure S2 ). We found that specific depletion of PKCl/i induced mesenchymal-to-epithelial transition (MET)-like response in MDA-MB-231 cells (Figures 2b and c) . Notably, these morphological changes of MDA-MB-231 also associated with significant inhibition in invasion through Matrigel-coated transwells and also migration during wound closure assays (Figures 2d-g ). To test whether PKCl/i signaling is a common positive regulator of invasion and migration, we depleted PKCl/i in multiple TNBC cell lines (Supplementary Figure S3a) . We found that depletion of PKCl/i significantly inhibited invasion and migration of multiple triple-negative breast cancer cells including MDA-MB-468 (EGFR-expressing and TP53 mutant), 39 BT-20 (constitutively active ER carrying deletion of exon 5, EGFR-expressing and TP53 mutant) 40 and HCC-1937 (EGFR-expressing, null for p53 expression and homozygous breast cancer 1, early onset (BRCA1) mutation carrier) 41 ( Supplementary Figures S3b and c) . We checked survival and proliferation of all the PKCl/idepleted TNBC cells and found no significant difference compared with the controls (Supplementary Figure S3d) . These results indicate that specific depletion of PKCl/i can inhibit the invasive potential of TNBC cells regardless of their TP53 status, EGFR expression and BRCA1 mutation without affecting their survival in vitro.
PKCk/i regulates TNBC growth, invasion and metastasis in vivo. Our in vitro analyses indicated that PKCl/i depletion in TNBC cells strongly inhibits their invasive potential ( Figure 2 and Supplementary Figure S3) . Furthermore, analysis in human patient samples showed that PKCl/i expression and phosphorylation are induced in all IDC Figure 1 Human breast cancers are associated with higher expression and phosphorylation of PKCl/i. Expression of PKCl/i (a) and phospho-PKCl/i (b) determined by Immunohistochemistry (IHC) in normal breast (n ¼ 10), DCIS (n ¼ 10) and IDC samples of ER þ subtype (n ¼ 10), HER2 þ subtype (n ¼ 10) and triple-negative subtype (n ¼ 35). Results were expressed as IHC scores of individual samples (by two independent pathologists) using a scale 0-3. IHC scores in between 0 to 1 considered as low expression, whereas IHC scores 41 considered as high expression. Expression of PKCl/i and phospho-PKCl/i in all IDC subtypes were significantly higher compared with DCIS and normal breast. P-values were calculated by two-way ANOVA with Bonferroni post-test (see also Supplementary Figure S1c subtypes including TNBC and metastatic breast cancers ( Figure 1 ). Thus, we tested whether PKCl/i signaling could promote TNBC growth and invasion in vivo. We orthotopically transplanted luciferase reporter expressing MDA-MB-231 (MDA-MB-231-luc) cells with or without PKCl/i depletion, into the mammary glands of immunodeficient mice (n ¼ 5) and monitor tumor growth via bioluminescence imaging (BLI) (Figure 3a) . We found that loss of PKCl/i resulted in significant inhibition in primary tumor growth within 5 weeks (Figure 3b -f and Supplementary Figure S4) . Importantly, similar to our observation in human IDC samples and metastatic breast cancers (Figures 1d and e) , we observed that PKCl/i predominantly localized in the cytoplasm and phospho-PKCl/i predominantly localized in the nuclei of the xenografted MDA-MB-231 cells (Figure 3g) .
Although PKCl/i depletion does not induce overt changes of TNBC cell proliferation during in vitro culture conditions (Supplementary Figure S3d) , our in vivo results suggest that the growth of primary tumors from orthotopically transplanted TNBC cells was dependent upon a cell-autonomous PKCl/i signaling. We reasoned that, during in vitro studies, a plethora of signaling molecules was present in high concentrations in serum-supplemented growth media and these signaling molecules might simultaneously activate multiple signaling cascades, thereby compensating the loss of PKCl/i signaling pathway. However, that compensation was absent in vivo as transplanted cells only had limited access to tissue specific growth factors or signaling molecules, which are highly regulated in a spatio-temporal manner within a complex environment and are present at their physiological concentrations.
Along with growth of primary tumors, we also assessed invasive progression of MDA-MB-231 cells in vivo upon PKCl/i depletion. We tested spontaneous metastasis of orthotopically transplanted MDA-MB-231 cells with and without PKCl/i depletion (n ¼ 5). We transplanted cells into the fourth mammary gland of immunodeficient mice, removed primary tumor at 5 weeks and observed for spontaneous metastasis to the lung (Figure 4a ). Again, we observed inhibition in orthotopic tumor growth upon PKCl/i depletion within 5 weeks (Figures 4b and 4c ) and also observed lung metastasis of control MDA-MB-231 cells 10 weeks after orthotopic transplantation (Figures 4d and e) . However, such an event was never observed after transplantation of PKCl/i-depleted MDA-MB-231 cells (Figures 4d and e) .
As, the primary tumor growth after orthotopic transplantation was itself inhibited upon PKCl/i depletion, the lack of metastatic lung colonization of PKCl/i-depleted MDA-MB-231 cells could be a secondary effect due to lack of primary tumor growth. Therefore, to further confirm the functional importance of PKCl/i during breast cancer metastasis, we transplanted both control and PKCl/i-depleted MDA-MB-231-luc cells intravenously via tail vein (n ¼ 5) and monitored for metastatic lung colonization via BLI (Figure 4f ). We observed significant inhibition in lung colonization with PKCl/i-depleted cells within 3 weeks (Figures 4g-i and Supplementary Figure  S5 ). Collectively, our functional analyses in animal models strongly indicate that PKCl/i signaling is important to promote TNBC growth, invasion and metastasis in vivo.
PKCk/i-regulated signature genes are associated with breast cancer invasive progression and poor clinical outcome. Although PKCl/i is highly expressed in IDC and metastatic breast cancers (Figure 1 ), we were unable to significantly correlate the PKCl/i mRNA expression data with clinicopathological parameters (Supplementary Figure S1a) . These results suggest that active, phosphorylated-PKCl/i forms (significantly high in IDC and metastatic breast cancers Figure 1 ) might be functionally more significant during breast cancer progression. Hence, we hypothesized that alteration of gene expression owing to PKCl/i signaling could be an indicative parameter to assess clinical outcome in breast cancer patients. To test this hypothesis, we investigated global gene expression changes in PKCl/i À depleted MDA-MB-231 cells via RNA sequencing (Figure 5a and Supplementary Table S1). We found that 2367 genes were downregulated and 1537 genes were upregulated upon PKCl/i depletion. Out of these PKCl/i-regulated genes, we selected 2234 genes, whose expressions were significantly altered in MDA-MB-231 cells after PKCl/i depletion and to be regulated by known transcription factors (via IPA resources www.ingenuity.com; Supplementary Table S2) . We evaluated expressions of those genes against publicly available breast cancer patient microarray data sets. We refined these genes to a set of 110 genes by a factor analysis-based filtering procedure (see details in Methods section) performed on a human breast cancer patient cohort of 31 DCIS, 36 IDC and 6 normal breast samples (Gene Expression Omnibus under accession GSE 26304). 42 The set of 110 signature genes (Supplementary Table S3 ) was subsequently termed the PKCl/i invasive signature 110 (PKCl/iIS110), and their expression patterns stratified patients into three distinct clusters; normal breast (group 1), DCIS (group2) and IDC (group3) with cluster independence P-value of 0.0108 and empirical P-value of 0.0026 based on Rand Index (Figures 5b and c) . Notably, a few basal-like (triple negative) DCIS cases clustered very closely with IDC groups indicating the similarity in molecular signatures between basal-like DCIS and IDC as reported earlier. 42 We observed that, among PKCl/iIS110, 45 genes are favorably overexpressed in the normal breast group (NB specific), 3 genes are specifically overexpressed in the DCIS group (DCIS-specific) and 62 genes are overexpressed in the IDC group (IDC specific) (Figures 5b and c) .
Next, we performed validation analysis with another independent human breast cancer patient cohort of seven DCIS and seven matched IDC samples (GSE3893-GPL570). 43 Although these matched samples have inherent tendency to cluster together, we observed that PKCl/iIS110 stratified almost all IDC patients (six out of seven) in one group and all DCIS patients into another distinct group (cluster independence P-value 0.0031 and empirical P-value based on Rand Index is 0.0031) (Figures 5d and e) . These data strongly indicate that altered expressions of PKCl/iIS110 genes could contribute to the invasive progression of breast cancer and PKCl/iIS110 gene set might serve as potential biomarkers to predict the DCIS to invasive breast cancer transition.
Consequently, we investigated whether downregulation of normal breast-specific genes or upregulation of IDC-specific genes of PKCl/iIS110 gene set could predict clinical outcome such as relapse or death in human breast cancer. We analyzed clinical relevance of the PKCl/iIS110 genes in a cohort of 159 human primary tumor samples representing breast cancer heterogeneity (25 basal-like or TNBC, 15 HER2-positive, 39 luminal-A, 23 luminal-B, 37 normal breastlike and 20 unclassified). 44 The PKCl/iIS110 genes showed clinically relevant clustering of these patients into three subgroups independent of the breast cancer molecular subtypes (Figure 5f ). Importantly, patients with loss of NBspecific genes and higher expression of IDC-specific genes predominantly clustered into the groups with poor clinical outcome (Group 2 and 3) (Figure 5g-i) . Similar observations were also observed in another independent data set of 286 lymph-node-negative patients with known ER status (GSE 2034). 45 The PKCl/iIS110 genes clustered patients into subgroups with significantly different clinical outcomes independent of ER status (Supplementary Figure S6) , and, again, loss of normal breast-specific genes or higher expression of IDC-specific genes indicated poor outcome ( Supplementary  Figures S6b and c) . Thus, our RNA-seq and multi-step bioinformatic analyses with gene expression data sets of human breast cancer patients have identified a PKCl/iregulated gene signature predictive of invasive progression of human breast cancer and poor clinical outcome.
Cytokine-PKCk/i-RelA regulatory axis positively modulates progression of breast cancer. As our analysis in microarray data sets of human breast cancer patients indicated clinical significance of differential expressions of PKCl/ iIS110 genes, we performed bio-function pathway analysis via ingenuity resources (IPA). We found that the expression pattern of PKCl/iIS110 genes in MDA-MB-231 cells indicated significant inhibition of various cellular pathways involved in cancer progression such as cell movement, migration, invasion and metastasis (Supplementary Figure  S7a) . Consequently, we wanted to understand potential signaling cascades regulating PKCl/iIS110 genes via activation of PKCl/i. Our analysis for upstream regulators potentially associated with the regulation of PKCl/iIS110 genes (via IPA) indicated that a majority of the PKCl/iIS110 genes could be regulated through various cytokines including TGFb, IL1b and TNFa (Supplementary Table S4 and Supplementary Figure S7b ). All these cytokines have been implicated in breast cancer progression previously. [46] [47] [48] To test the effect of these cytokines on PKCl/i activation, we treated MDA-MB-231 cells with different cytokines and tested phosphorylation of PKCl/i. Intriguingly, we found that both TGFb1 and IL1b, individually and in combination, induced PKCl/i phosphorylation in MDA-MB-231 cells (Figure 6a and Supplementary Figure S8a) . However, we did not observe induction of PKCl/i phosphorylation upon TNFa treatment (Supplementary Figure S8a) . Interestingly, we also observed that cytokine-induced phospho-PKCl/i molecules are predominantly localized within the nuclei of MDA-MB-231 cells (Figure 6b ). Taken together, these data strongly indicate that cytokines, like TGFb and IL1b, might induce PKCl/i activation in TNBC cells and facilitate nuclear translocation of phospho-PKCl/i as observed in our xenogtraft models as well as in IDC and metastatic breast cancers (Figure 1 and Figure 3g ).
To link different cytokine signaling nodes and PKCl/i, we looked for a common downstream regulator. Interestingly, earlier reports implicated atypical PKC signaling in regulating NF-kB p65 (RelA) function in multiple cell types, 49, 50 and RelA has a known association with various cytokine networks 51, 52 (Supplementary Figure S7b) . As RelA is one of the major transcription factors that inhibited upon PKCl/i depletion in MDA-MB-231 cells (as predicted by IPA in Supplementary Table S3) , we tested RelA expression in multiple TNBC cells along with HER2-positive BT474 and ER þ MCF-7 cells. We found that RelA was highly abundant in all these cell types (Supplementary Figure S8b) . Thus, we hypothesized that a PKCl/i-RelA signaling axis might regulate the expression of at least some of the PKCl/iIS110 genes during breast cancer disease progression. For confirmation, we tested RelA nuclear localization and activity in MDA-MB-231 cells after PKCl/i depletion. We observed significant reduction of RelA nuclear localization in MDA-MB-231 cells after PKCl/i depletion (Figures 6c, 6d and Supplementary Figure S8c) . We confirmed no significant changes in the total RelA expression level in MDA-MB-231 cells after PKCl/i depletion (Figure 6d ). To validate compromised RelA function, we performed NF-kB reporter gene analysis and observed significant repression of NF-kB transcription activity in the PKCl/i-depleted MDA-MB-231 cells (Figure 6e) . For further confirmation, we measured mRNA expression levels of known RelA target genes from PKCl/iIS110 signature panel such as ICAM1 (intercellular adhesion molecule 1) 53 and PLAU (plasminogen activator, Urokinase) 54 and also the genes that contain consensus RelA-binding motifs at the promoter regions such as DAB2 (Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)) and VIM (Vimentin) (Supplementary Figure S8d) . We observed significant downregulation of these genes in PKCl/i-depleted cells compared with control (Figure 6f) . Furthermore, RelA chromatin occupancy at the consensus RelA-binding motifs present in the promoter regions of these genes was also impaired (Figure 6g ).
To confirm further that RelA transcriptional activity downstream to PKCl/i signaling might contribute to gene regulation and invasiveness of TNBC cells, we ectopically expressed a constitutively active RelA mutant (RelA-S536E) 55 in PKCl/idepleted MDA-MB-231 cells (Supplementary Figure S9) . We observed that ectopic expression of RelA-S536E partially rescues expression of RelA target genes in PKCl/i-depleted MDA-MB-231 cells and promotes their invasiveness when tested via in vitro invasion assay (Supplementary Figure S9) . These results strongly indicate that a cytokine-PKCl/i-RelA signaling axis might be involved in gene regulation to positively modulate invasive and metastatic progression of breast cancer cells (Figure 6h ).
Discussion
In this study, we provided evidence that PKCl/i signaling positively regulates TNBC invasion and metastasis. Specific depletion of PKCl/i inhibited invasiveness of multiple TNBC breast cancer cell types with mutant TP53, EGFR overexpression and BRCA1 mutation. All these genetic abnormalities are significantly associated with poor prognosis. 8, 56 Importantly, depletion of PKCl/i significantly inhibited TNBC growth and metastatic lung colonization in experimental animal models. These observations indicate that targeting PKCl/i signaling might have therapeutic potential for TNBC relapse and metastasis.
During breast cancer progression, transitions from normal breast to DCIS and then to IDC are associated with important developmental changes. However, to date, the molecular basis of these developmental changes is poorly understood. Intriguingly, we observed a gradual increase in PKCl/i signaling from normal breast to DCIS to IDC samples of multiple clinical subtypes, indicating that gradual increase in PKCl/i activity might be important for altered gene expression circuitry associated with breast cancer progression. Consistently, our global gene expression analysis in breast cancer cells and human breast cancer patient data sets identified a PKCl/i dependent gene signature (PKCl/iIS110) differentially expressed between normal breast, DCIS and IDC samples. We also observed that differential expression of IDC-specific genes of PKCl/iIS110 is significantly associated with poor clinical outcome such as relapse and death of breast cancer patients. Thus, PKCl/iIS110 could be of tremendous clinical significance and might serve as a platform to identify specific biomarkers, which could predict invasive progression of breast cancer. Altogether, these observations and previous reports 28, 29 indicate significance of PKCl/i signaling during the breast cancer disease progression including growth, invasion, relapse/metastasis and survival.
Mechanistically, we have identified cytokine-PKCl/i-NF-kB signaling axis, which could regulate key genes associated with breast cancer progression and metastasis. IPA analysis identified that depletion of PKCl/i resulted in inhibition of multiple cytokine signaling nodes such as TGFb1 and IL-1b; both cytokines are known to control expressions of various migration-and metastasis-related genes. 57, 58 Supporting IPA clustering of an independent human patient data set GSE3893-GPL570 containing matched DCIS and IDCs (n ¼ 14) using PKCl/iIS110 feature vector. While these samples show a natural tendency to cluster by patient, k-means clustering with PKCl/iIS110 feature vector distinctly groups them according to their disease type. The color gradient of the heatmap represents normalized expression values from high (red) to low (blue). All DCIS patients clustered in Group 1 (purple bar along the top), and six out of seven IDC patients clustered in Group 2 (red bar) indicating the validity of PKCl/iIS110 signature gene set to predict invasive phenotype of breast cancer. (e) Mean expression and expression polarization P-values of PKCl/iIS110 genes between patient groups of data set GSE3893-GPL570. (f) Heatmap representing unsupervised k-means (k ¼ 3) clustering in human patient data set GSE1456 (n ¼ 159) using PKCl/iIS110 feature vector. The color gradient of the heatmap represents normalized expression values from high (red) to low (blue). Group 1 (blue bar along the top), Group 2 (purple bar) and Group 3 (red bar). (g) Mean expression and expression polarization P-values of PKCl/iIS110 genes between patient groups of data set GSE1456. (h) Kaplan-Meier estimates of the time-to-relapse of patient samples (from GSE1456 cohort) of groups 2 (purple) and 3 (red) were compared with group 1 (blue). The P-values were calculated using the log-rank test. Patient group 1 (blue) showed better prognosis compared with groups 2 and 3. (i) Kaplan-Meier estimates of time-to-death due to breast cancer of patient samples (from GSE1456 cohort) of groups 2 (purple) and 3 (red) were compared with group 1(blue). The P-values were calculated using the log-rank test. Patient group1 (blue) showed better prognosis compared with groups 2 and 3 analysis, we found that TGFb1 and IL-1b could induce phosphorylation as well as nuclear translocation of PKCl/i in TNBC cells. Previously, various lipids and growth factors, such as ceramide, phosphoinositide 3-kinase (PI3K), 3 phosphoinositide-dependent protein kinase-1 (PDK-1), EGF, NGF, PDGF and HER2, have been implicated as the upstream regulators to activate PKCl/i. 15, 31 Thus, it is possible that TGFb1 and IL-1b could modulate these known activators of PKCl/i to induce phosphorylation at Thr555/Thr563. However, further research is required to investigate specific molecular mechanism.
We also observed that NF-kB p65 or RelA transcriptional activity in TNBC cells could be regulated by PKCl/i signaling. Furthermore, rescue of invasive phenotype of PKCl/idepleted MDA-MB-231 cells upon ectopic expression of constitutively active RelA-S536E molecules strongly indicates that a PKCl/i-RelA signaling axis, at least in part, might contribute to the invasive progression of TNBC cells. However, our global gene expression analysis also indicated that depletion of PKCl/i signaling could repress additional transcriptional networks, such as hypoxia-inducible factor 1alpha (HIF1a), signal transducer and activator of transcriptions (STATs) and SMAD3, known to function downstream of various cytokine and growth factor signaling networks to promote breast cancer invasion and metastasis.
14 These observations imply the existence of overlapping regulatory mechanisms involving PKCl/i and other signaling cascades to promote invasive progression of breast cancer, and future studies in this direction could provide important information.
In summary, we discovered that PKCl/i signaling mediates survival adaptability of breast cancer cells in their natural milieu, that is, in the breast, and promotes metastasis in distal tissues such as the lung by regulating NF-kB and other cytokine and growth factor-associated transcription factors. Thus, our study raised a possibility to treat highly heterogeneous breast cancer disease by targeting PKCl/i signaling and its upstream and downstream regulatory molecules.
Materials and Methods
Analysis of human primary breast tumor samples. The tissue microarray slides consisting of 55 IDC samples (10 ER positive, 10 HER2 positive, 35 TNBC), 10 DCIS samples and 10 normal breast tissues were prepared by the University of Kansas Medical Center Department of Pathology from archival material following IRB approval. Expressions of both PKCl/i and phospho-PKCl/i were analyzed by immunohistochemistry (IHC). Digital images of the stained slides were taken using Aperio TMA software, and expressions of PKCl/i and phosphoPKCl/i were analyzed by two independent pathologists in a double-blind manner. The expression levels (IHC scores) were indicated in a scale of 0 to 3, where 3 indicates highest and 0 indicates lowest expressions. IHC scores 0 to 1 and 41 were considered as low and high expression, respectively. For significance, P-values were calculated by two-way ANOVA with Boneferroni post-test (Supplementary Figures S1c-f) .
Cell lines. All breast cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained according to the recommended protocol. For knockdown of PKCl/i, cell lines were infected with lentiviral pGIPZ shRNAmir vector containing short hairpins and GFP reporter (Supplementary Table S5 ) (Open Biosystems, Pittsburgh, PA, USA).
Animal studies. All animal works were done in accordance with approved protocol by the Institutional Animal Care and Use Committee. Female NU/NU nude and NOD-SCID NSG mice (Charles River) of 4-6 weeks old (n ¼ 5 for cell line for each in vivo experimental set) were used in xenograft studies for lung metastasis and orthotopic mammary fat pad tumor assays. Two different shRNA constructs showed most effective knockdown of PKCl/i and subsequently used to knockdown PKCl/i in TNBC cells including MDA-MB-231-luc or MDA-MB-231 cells that were used for animal studies.
For orthotopic tumor assays, cells were collected in PBS. Mice were anesthetized, a small incision was made to reveal the mammary gland and 2 Â 10 6 cells were injected directly into the second or fourth mammary glands. The incision was closed with wound clips, and primary tumor outgrowth was monitored weekly. For spontaneous metastasis assays, primary tumors were surgically removed after 5 weeks and kept for another 5 weeks for the development of metastasis in the lungs.
For lung colonization assay, 1 Â 10 6 viable cells were injected into the lateral tail vein in a volume of 0.1 ml. Following isoflurane-induced anesthesia, mice were imaged for luciferase activity immediately after injection to exclude any that were not successfully xenografted. Lung colonization was monitored weekly and continued up to 3 weeks.
Bioluminescent imaging. Mice were anesthetized and injected intraperitoneally (IP) with D-luciferin (15 mg/ml in PBS and 0.01 ml/g bodyweight). Imaging was performed after injection with a Xenogen IVIS system coupled to Living Image acquisition and analysis software version 4.0 (Xenogen, Hopkinton, MA, USA). Region of interest (ROI) boxes were drawn around the entire body (excluding tail) of the animals. Measurements were expressed as flux (i.e., photons/second) and scaled to a comparable background value (from a luciferin-injected mouse with no tumor cells). For normalization, the flux values obtained immediately after xenografting (day 0) were considered as 100 so that all mice had an arbitrary starting BLI signal of 100.
RNA-Seq analysis and Gene set Enrichment Analysis. We used whole-transcriptome shotgun sequencing (RNA-Seq) to obtained the global gene expression profile of MDA-MB-231 cells after PKCl/i depletion by RNAi carried out independently using two different shRNA clones (shRNA1 and shRNA2, Supplementary Table S5 ) and compared it with the expression profile under control conditions (control shRNA, Supplementary Table S5 ). Detailed methods were described in Supplementary Materials and Methods.
Patient data set analysis. All genes were normalized to the geometric average of the three housekeeping genes MRPL19, PSMC4 and PUM1, as these genes showed minimal variation in expression across a variety of experimental conditions. 59 Genes with multiple probesets were represented by the probeset with maximal variance across samples. The significance of the partitions generated by k-means clustering for the 110 gene feature vector (PKCl/iIS110) was evaluated as an empirical P-value calculated on the w 2 -statistic of cluster independence as follows:
, where c is the number of clusterings for randomly selected genes of the same size as the signature gene set that generated a w 2 -statistic equal to or greater than the observed w 2 -statistic and N (10,000) the number of random tests performed. The empirical P-value based on the Rand regulatory axis for breast cancer growth, invasion and metastasis index was calculated similarly giving an alternate assessment of the significance of the generated clusters. Here P Rand ¼ (r þ 1)/(N þ 1) where r is the number of clusterings for randomly selected genes of the same size as the signature gene set that generated a Rand measure equal to or greater than the observed Rand measure and N (10,000) the number of random tests performed. Population survival or remission curves were compared using the log-rank test. The survival function was estimated using the Kaplan-Meier procedure. Gene expression levels were standardized (mean 0 and S.D. 1) across samples for visualization. Expression polarization was defined as the absolute difference between the mean expression levels over the genes and patients in each group, and P-values of the observed expression polarization was calculated as described earlier. 60 Among the 3904 significantly differentially expressed genes in the RNA-Seq experiments, 2234 genes were identified that were associated with significantly inhibited or activated upstream regulators as predicted by IPA. With these genes as observations and samples as variables, the data set GSE26304 was factor analyzed with three common factors. The factor solution was rotated using the 'varimax' procedure for better interpretation. Genes with an absolute correlation coefficient Z0.6 with the factor loadings of any one of the factors were selected to comprise the signature set of 110 genes (PKCl/iIS110). These 110 signature genes formed the feature vector for further k-means clustering on the data sets GSE26304, GSE3893-GPL570, GSE1456 and GSE 2034. Kaplan-Meier estimation was performed using time-to-death due to breast cancer or censoring and timeto-relapse or last follow-up for GSE1456 and GSE 2034 data sets. Genes from the data set GSE26304 were hierarchically clustered using the Euclidian pair-wise distance between rows and the 'ward' method for the linkage function to establish the signature gene order.
Statistics. All statistical analyses were performed using GraphPad Prism5 statistical software (GraphPad Software Inc., San Diego, CA, USA) unless mentioned otherwise. All data are expressed as means±S.E.M. unless mentioned otherwise. P-values were calculated by two-tailed unpaired Student's t-test, one-way or two-way ANOVA with Bonferroni post-test unless mentioned otherwise, and Po0.05 was considered as significant.
